Comparative Pharmacology
Head-to-head clinical analysis: CARBINOXAMINE MALEATE versus PHENETRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBINOXAMINE MALEATE versus PHENETRON.
CARBINOXAMINE MALEATE vs PHENETRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbinoxamine maleate is a first-generation antihistamine that competitively inhibits histamine at H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
Adults: 4-8 mg orally every 6-8 hours as needed. Maximum: 24 mg/day.
Adults: 50 mg intramuscularly every 6 hours as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment, requiring dose adjustment in significant liver disease.
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Primarily renal excretion of metabolites and unchanged drug; ~60-70% of a dose is excreted in urine within 48 hours, with less than 5% as unchanged drug. Biliary/fecal elimination accounts for a minor fraction (<10%).
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Category C
Category C
Antihistamine
Antihistamine